{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:07:33Z","timestamp":1789016853296,"version":"build-2803163510"},"reference-count":107,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2025LSW045"],"award-info":[{"award-number":["ZR2025LSW045"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) develops when hepatic lipid acquisition and synthesis exceed the capacity for oxidation and very-low-density lipoprotein export. Flavonoids act on several components of this network, yet their therapeutic development is constrained by poor aqueous solubility, extensive intestinal and first-pass metabolism, variable activity of circulating metabolites, and limited information on hepatic exposure. Experimental studies link representative flavonoids to AMPK\u2013SREBP-1c and PPAR\u03b1 signaling, mitochondrial quality control, Nrf2-dependent redox defense, inflammatory pathways, and the gut\u2013liver axis. By contrast, the available randomized trials of quercetin, hesperidin, anthocyanins, green-tea catechins, EGCG, and soy isoflavones show at most modest changes in liver fat or biochemical markers and do not demonstrate metabolic dysfunction-associated steatohepatitis (MASH) resolution or fibrosis regression. Liposomal, lipid-based, polymeric, and nanocrystal formulations have improved dissolution, systemic exposure, or liver distribution in preclinical models, but comparative pharmacokinetics, chronic safety, manufacturability, and clinical efficacy remain poorly defined. The evidence therefore supports viewing flavonoids as formulation-dependent investigational candidates rather than established MASLD therapies. Progress will depend on chemically standardized products, exposure\u2013response studies, clinically relevant models, and adequately powered trials using validated imaging or histological endpoints.<\/jats:p>","DOI":"10.3390\/ph19091393","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:35:29Z","timestamp":1788359729000},"page":"1393","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies"],"prefix":"10.3390","volume":"19","author":[{"given":"Shuo","family":"Yan","sequence":"first","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejian","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Hao","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dom.70659","article-title":"Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment","volume":"28","author":"Romanos","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2014A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Guo, X., Yin, X., Liu, Z., and Wang, J. (2022). Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415489"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nassir, F. (2022). NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12.","DOI":"10.3390\/biom12060824"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women with Nonalcoholic Fatty Liver Disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DDDT.S560039","article-title":"Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential","volume":"20","author":"Alamgir","year":"2026","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10408398.2014.952399","article-title":"The potential of flavonoids in the treatment of non-alcoholic fatty liver disease","volume":"57","author":"Koek","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114991","DOI":"10.1016\/j.biopha.2023.114991","article-title":"The great potential of flavonoids as candidate drugs for NAFLD","volume":"164","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinre.2016.07.001","article-title":"Non-alcoholic fatty liver disease and flavonoids: Current perspectives","volume":"41","author":"Shin","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2174\/0929867327666200713184138","article-title":"Recent Research on Flavonoids and their Biomedical Applications","volume":"28","author":"Wen","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5445291","DOI":"10.1155\/2022\/5445291","article-title":"Flavonoids a Bioactive Compound from Medicinal Plants and Its Therapeutic Applications","volume":"2022","author":"Roy","year":"2022","journal-title":"BioMed Res. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ravetti, S., Garro, A.G., Gait\u00e1n, A., Murature, M., Galiano, M., Brignone, S.G., and Palma, S.D. (2023). Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030863"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3945\/an.113.004648","article-title":"Hepatic Fatty Acid Trafficking: Multiple Forks in the Road","volume":"4","author":"Mashek","year":"2013","journal-title":"Adv. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/scisignal.272re3","article-title":"CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior","volume":"2","author":"Silverstein","year":"2009","journal-title":"Sci. Signal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated with Diet-Induced Obesity","volume":"56","author":"Koonen","year":"2007","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/en.2015-1866","article-title":"Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice","volume":"157","author":"Wilson","year":"2016","journal-title":"Endocrinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","article-title":"Targeted Deletion of FATP5 Reveals Multiple Functions in Liver Metabolism: Alterations in Hepatic Lipid Homeostasis","volume":"130","author":"Doege","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"22186","DOI":"10.1074\/jbc.M803510200","article-title":"Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia","volume":"283","author":"Doege","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1194\/jlr.R056705","article-title":"Recent insights into the biological functions of liver fatty acid binding protein 1","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: Master regulators of lipid homeostasis","volume":"86","author":"Hegarty","year":"2004","journal-title":"Biochimie"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1074\/jbc.M111421200","article-title":"Diminished Hepatic Response to Fasting\/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c","volume":"277","author":"Liang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Guo, X., Zheng, J., Zhang, S., Jiang, X., Chen, T., Yu, J., Wang, S., Ma, X., and Wu, C. (2021). Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD. Front. Clin. Diabetes Healthc., 2.","DOI":"10.3389\/fcdhc.2021.691828"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.nutr.21.1.193","article-title":"Peroxisomal \u03b2-oxidation and peroxisome proliferator-activated receptor \u03b1: An adaptive metabolic system","volume":"21","author":"Reddy","year":"2001","journal-title":"Annu. Rev. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"G852","DOI":"10.1152\/ajpgi.00521.2005","article-title":"Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation","volume":"290","author":"Reddy","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of Mitochondria in Nonalcoholic Fatty Liver Disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bourouh, M., and Marignani, P.A. (2022). The Tumor Suppressor Kinase LKB1: Metabolic Nexus. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.881297"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Feng, J., Li, M., Yao, T., Yi, X., and Gao, H. (2025). Research progress on AMPK in the pathogenesis and treatment of MASLD. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1558041"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109414","DOI":"10.1016\/j.jnutbio.2023.109414","article-title":"Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy","volume":"120","author":"Cao","year":"2023","journal-title":"J. Nutr. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bbrc.2008.06.077","article-title":"The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways","volume":"373","author":"Ahn","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1039\/C9FO02237F","article-title":"Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice","volume":"11","author":"Sun","year":"2020","journal-title":"Food Funct."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.nutres.2011.09.026","article-title":"Purple sweet potato anthocyanins attenuate hepatic lipid accumulation through activating adenosine monophosphate\u2013activated protein kinase in human HepG2 cells and obese mice","volume":"31","author":"Hwang","year":"2011","journal-title":"Nutr. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nutres.2015.11.019","article-title":"Quercetin regulates hepatic cholesterol metabolism by promoting cholesterol-to-bile acid conversion and cholesterol efflux in rats","volume":"36","author":"Zhang","year":"2016","journal-title":"Nutr. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tie, F., Ding, J., Hu, N., Dong, Q., Chen, Z., and Wang, H. (2021). Kaempferol and Kaempferide Attenuate Oleic Acid-Induced Lipid Accumulation and Oxidative Stress in HepG2 Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168847"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1039\/D0FO02736G","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD","volume":"12","author":"Li","year":"2021","journal-title":"Food Funct."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jn\/137.5.1127","article-title":"Genistein Downregulates SREBP-1 Regulated Gene Expression by Inhibiting Site-1 Protease Expression in HepG2 Cells","volume":"137","author":"Shin","year":"2007","journal-title":"J. Nutr."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Goldwasser, J., Cohen, P.Y., Yang, E., Balaguer, P., Yarmush, M.L., and Nahmias, Y. (2010). Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the Grapefruit Flavonoid Naringenin: Role of PPAR\u03b1, PPAR\u03b3 and LXR\u03b1. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012399"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/db09-0634","article-title":"Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor\u2013Null Mice With Diet-Induced Insulin Resistance","volume":"58","author":"Mulvihill","year":"2009","journal-title":"Diabetes"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1017\/S000711451100225X","article-title":"Up-regulation of PPAR\u03b3, heat shock protein-27 and -72 by naringin attenuates insulin resistance, \u03b2-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes","volume":"106","author":"Sharma","year":"2011","journal-title":"Br. J. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115113","DOI":"10.1016\/j.biopha.2023.115113","article-title":"Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1\/AMPK signaling pathway","volume":"165","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-024-05060-7","article-title":"Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK\/PGC-1\u03b1 and PPAR\u03b1-mediated autophagy pathway","volume":"22","author":"Yang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Madduma Hewage, S., Au-Yeung, K.K.W., Prashar, S., Wijerathne, C.U.B., O, K., and Siow, Y.L. (2022). Lingonberry Improves Hepatic Lipid Metabolism by Targeting Notch1 Signaling. Antioxidants, 11.","DOI":"10.3390\/antiox11030472"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00394-013-0516-8","article-title":"Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF\/SMAD, PI3 K\/Akt\/FoxO1, and NF-kappa B pathways","volume":"53","author":"Xiao","year":"2014","journal-title":"Eur. J. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2016.11.037","article-title":"Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation","volume":"102","author":"Porras","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Roy, S., Saha, P., Bose, D., Trivedi, A., More, M., Xiao, S., Diehl, A.M., and Chatterjee, S. (2023). Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216354"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"117527","DOI":"10.1016\/j.taap.2025.117527","article-title":"Peroxynitrite is key to Cylindrospermopsin-mediated MASLD to MASH progression via triggering TXNIP binding to NLRP3 and subsequent inflammasome activation","volume":"504","author":"Saha","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Friuli, M., Sepe, C., Panza, E., Travelli, C., Paterniti, I., and Romano, A. (2024). Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: Evidence for novel pharmacological strategies?. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1407336"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1080\/09168451.2019.1608807","article-title":"Citrus peel flavonoids improve lipid metabolism by inhibiting miR-33 and miR-122 expression in HepG2 cells","volume":"83","author":"Su","year":"2019","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/nu5030637","article-title":"Naringin Improves Diet-Induced Cardiovascular Dysfunction and Obesity in High Carbohydrate, High Fat Diet-Fed Rats","volume":"5","author":"Alam","year":"2013","journal-title":"Nutrients"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jnutbio.2011.12.009","article-title":"Citrus unshiu peel extract ameliorates hyperglycemia and hepatic steatosis by altering inflammation and hepatic glucose- and lipid-regulating enzymes in db\/db mice","volume":"24","author":"Park","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ptr.5256","article-title":"Antioxidant and Anti-Inflammatory Properties of the Citrus Flavonoids Hesperidin and Hesperetin: An Updated Review of their Molecular Mechanisms and Experimental Models","volume":"29","author":"Parhiz","year":"2015","journal-title":"Phytother. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3164\/jcbn.09-82","article-title":"Dietary Hesperidin Exerts Hypoglycemic and Hypolipidemic Effects in Streptozotocin-Induced Marginal Type 1 Diabetic Rats","volume":"46","author":"Akiyama","year":"2010","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1194\/jlr.M013375","article-title":"Anthocyanin inhibits high glucose-induced hepatic mtGPAT1 activation and prevents fatty acid synthesis through PKC\u03b6","volume":"52","author":"Guo","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jn\/138.2.323","article-title":"Green Tea Extract Protects Leptin-Deficient, Spontaneously Obese Mice from Hepatic Steatosis and Injury","volume":"138","author":"Bruno","year":"2008","journal-title":"J. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12263-013-0373-3","article-title":"Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats","volume":"9","author":"Xiao","year":"2014","journal-title":"Genes Nutr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/ptr.7526","article-title":"Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways","volume":"36","author":"Pham","year":"2022","journal-title":"Phytother. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jnutbio.2012.03.014","article-title":"Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice","volume":"24","author":"Lee","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.05.009","article-title":"Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial","volume":"99","author":"Chen","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bbrc.2016.11.101","article-title":"Luteolin improves non-alcoholic fatty liver disease in db\/db mice by inhibition of liver X receptor activation to down-regulate expression of sterol regulatory element binding protein 1c","volume":"482","author":"Yin","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7996","DOI":"10.1038\/s41598-023-34654-2","article-title":"Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice","volume":"13","author":"Lu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"35766","DOI":"10.1038\/s41598-025-96848-0","article-title":"Effect and mechanism of fisetin against the development of metabolic dysfunction-associated fatty liver disease","volume":"15","author":"Peng","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/MD.0000000000000758","article-title":"A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients with Nonalcoholic Fatty Liver Disease","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3892\/ijmm.2013.1503","article-title":"Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study","volume":"32","author":"Sakata","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/2008-7802.173051","article-title":"The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease","volume":"7","author":"Pezeshki","year":"2016","journal-title":"Int. J. Prev. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.clnu.2024.06.018","article-title":"Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4","volume":"43","author":"Yang","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipi\u010d, M., Frutos, M.J., Galtier, P., and Gott, D. (2018). Scientific opinion on the safety of green tea catechins. EFSA J., 16, e05239.","DOI":"10.2903\/j.efsa.2018.5239"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1080\/19390211.2022.2128501","article-title":"Hepatotoxicity with High-Dose Green Tea Extract: Effect of Catechol-O-Methyltransferase and Uridine 5\u2019-Diphospho-glucuronosyltransferase 1A4 Genotypes","volume":"20","author":"Acosta","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Neshatbini Tehrani, A., Hatami, B., Daftari, G., Hekmatdoost, A., Yari, Z., Salehpour, A., Hosseini, S.A., and Helli, B. (2024). The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: A randomized placebo controlled clinical trial. BMC Public Health, 24.","DOI":"10.1186\/s12889-024-18812-3"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Zy\u015bk, B., Ostrowska, L., Smarkusz-Zarzecka, J., Orywal, K., Mroczko, B., and Cwalina, U. (2024). Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD\u2014A Pilot Study. Nutrients, 16.","DOI":"10.3390\/nu16091381"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Saeed, A., Dullaart, R., Schreuder, T., Blokzijl, H., and Faber, K. (2017). Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 10.","DOI":"10.3390\/nu10010029"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mylonis, I., Simos, G., and Paraskeva, E. (2019). Hypoxia-Inducible Factors and the Regulation of Lipid Metabolism. Cells, 8.","DOI":"10.3390\/cells8030214"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2415846","DOI":"10.1002\/advs.202415846","article-title":"Asprosin-FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPAR\u03b1 Contributing to MASLD Development","volume":"12","author":"Yu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease\u2014Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41598-018-19553-1","article-title":"Chinese olive extract ameliorates hepatic lipid accumulation in vitro and in vivo by regulating lipid metabolism","volume":"8","author":"Yeh","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Liang, M., Huo, M., Guo, Y., Zhang, Y., Xiao, X., Xv, J., Fang, L., Li, T., Wang, H., and Dong, S. (2022). Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1084435"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Pan, J., Liu, H., and Jiao, Z. (2023). Characterization of the Synergistic Antioxidant Activity of Epigallocatechin Gallate (EGCG) and Kaempferol. Molecules, 28.","DOI":"10.3390\/molecules28135265"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Dai, W., Bi, J., Li, F., Wang, S., Huang, X., Meng, X., Sun, B., Wang, D., Kong, W., and Jiang, C. (2019). Antiviral Efficacy of Flavonoids against Enterovirus 71 Infection in Vitro and in Newborn Mice. Viruses, 11.","DOI":"10.3390\/v11070625"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.plaphy.2021.05.023","article-title":"The role of quercetin in plants","volume":"166","author":"Singh","year":"2021","journal-title":"Plant Physiol. Biochem."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Liu, Q., Luan, H., Duan, Z., Ai, J., Wang, Y., and Chen, P. (2025). Efficacy of flavonoids in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1660065"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lfs.2018.10.066","article-title":"Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: An update","volume":"215","author":"Joshi","year":"2018","journal-title":"Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00228-017-2345-9","article-title":"The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects","volume":"74","author":"Bedada","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2217\/nnm-2017-0119","article-title":"Nanoliposome Improves Inhibitory Effects of Naringenin on Nonalcoholic Fatty Liver Disease in Mice","volume":"12","author":"Chen","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1166\/jbn.2021.3077","article-title":"Study on the Inhibitory Effects of Naringenin-Loaded Nanostructured Lipid Carriers Against Nonalcoholic Fatty Liver Disease","volume":"17","author":"Hu","year":"2021","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1208\/s12249-017-0790-5","article-title":"Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement","volume":"18","author":"Gera","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"130950","DOI":"10.1016\/j.foodchem.2021.130950","article-title":"A comparative study of optimized naringenin nanoformulations using nano-carriers (PLA\/PVA and zein\/pectin) for improvement of bioavailability","volume":"369","author":"Smruthi","year":"2022","journal-title":"Food Chem."},{"key":"ref_105","first-page":"100246","article-title":"Fabrication and in vitro\/vivo evaluation of quercetin nanocrystals stabilized by glycyrrhizic acid for liver targeted drug delivery","volume":"7","author":"Shen","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"114423","DOI":"10.1016\/j.colsurfb.2024.114423","article-title":"Naringenin loaded solid lipid nanoparticles alleviate oxidative stress and enhance oral bioavailability of naringenin","volume":"247","author":"Zaheer","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e71617","DOI":"10.1002\/fsn3.71617","article-title":"Hepatoprotective Effects of Quercetin-Chitosan Nanoparticles on Nonalcoholic Fatty Liver Disease: In Vivo Study","volume":"14","author":"Babaalizadeh","year":"2026","journal-title":"Food Sci. Nutr."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1393\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:14:36Z","timestamp":1789013676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091393"],"URL":"https:\/\/doi.org\/10.3390\/ph19091393","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}